Treatment Holidays for Patients With Metastatic Colorectal Cancer
Mené sur 254 patients atteints d'un cancer colorectal métastatique stable ou répondant à un traitement de première ligne d'une durée de 16 semaines, cet essai évalue l'intérêt, du point de vue de la survie sans progression et de l'absence de réduction de la survie globale, et la tolérabilité d'un traitement oral d'entretien par capécitabine
Therapy for metastatic colorectal cancers is palliative in intent for most patients. In this situation, treatment typically includes sequential combinations of chemotherapies paired with a biologic, followed by drugs such as regorafenib and trifluridine-tipiracil in the salvage setting.1 These regimens, used alongside advances in surgery and allied fields, have improved the survival of patients with metastatic colorectal cancer from a median of 6 months from diagnosis to recent clinical trials reporting upward of a median of 42 months for all-comers.